Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/221691
Title: | Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study |
Author: | Zugasti, Inés López Guerra, Mònica Castaño Díez, Sandra Esteban, Daniel Avendaño Pita, Alejandro Pomares, Helena Pérez, Ana García Ávila, Sara Padilla Conejo, Irene Fuente Montes, Cristina de la Martínez Roca, Alexandra Merchán Muñoz, Beatriz Jiménez Vicente, Carlos Guijarro Tomas, Francisca Ramón Álamo, José Cortés Bullich, Albert Torrecillas, Victor Mont de Torres, Lucía Carcelero, Esther Riu Viladoms, Gisela Zamora, Lurdes Bargay, Joan Triguero, Ana Suarez Lledó, María Queralt Salas, Maria López Cadenas, Felix Ramos, Fernando Xicoy Cirici, Blanca Valcárcel, David Arnan, Montserrat Martínez, Carmen Rovira, Montserrat Fernández Avilés, Francesc Díez Campelo, María Esteve Reyner, Jordi Díaz Beyá, Marina |
Keywords: | Leucèmia mieloide Terapèutica Myeloid leukemia Therapeutics |
Issue Date: | 26-Apr-2025 |
Publisher: | Springer Science and Business Media LLC |
Abstract: | BackgroundHigh-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML) remain therapeutic challenges with suboptimal outcomes. The only potentially curative treatment is allogeneic stem cell transplantation (allo-SCT). The most frequent pre-allo-SCT treatment is monotherapy with hypomethylating agents (HMA), but approximately 40% of patients cannot proceed to allo-SCT, mainly due to disease progression. Recent evidence suggests that combining HMA with venetoclax (HMA/VEN) could increase HMA efficacy in HR-MDS but it remains unclear if this combination could bridge more patients to allo-SCT.MethodsWe retrospectively evaluated HMA/VEN as a bridge to allo-SCT in 30 patients with HR-MDS or CMML eligible for transplant. Eighteen patients were treatment-na & iuml;ve and 12 were refractory or relapsed (R/R).ResultsAs defined by the IWG 2023 criteria, the overall response rate (ORR) was 90% and the composite complete response rate was 77%. For the R/R patients, ORR was 83%. The allo-SCT rate was 83%, and the allo-SCT rate of those patients treated exclusively with HMA/VEN without further bridge therapies was 76%. One- and two-year post-allo-SCT survival was 75% and two-year cumulative incidence of relapse was 30.5%. Follow-up of measurable residual disease identified some molecular relapses that were controlled with preemptive treatment.ConclusionsOur findings indicate that HMA/VEN combination therapy shows promise as a bridging strategy to allo-SCT in HR-MDS and CMML. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s40164-025-00652-5 |
It is part of: | Experimental Hematology and Oncology, 2025, vol. 14 |
URI: | https://hdl.handle.net/2445/221691 |
Related resource: | https://doi.org/10.1186/s40164-025-00652-5 |
ISSN: | 2162-3619 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s40164-025-00652-5.pdf | 2.19 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License